Simplifying Software Security: Veracode Enhances Frictionless Experience for Developers
14.9.2022 21:33:00 EEST | Business Wire | Press release
Black Hat (booth #2428) – Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform with substantial improvements to its integrated developer experience. New features include extended integrations to support software composition analysis (SCA), a software bill of materials (SBOM) Application Programming Interface (API), and additional language and framework support for static analysis, further enhancing developers’ ability to secure software in the environments where they work.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220809005141/en/
Fig. 1 Veracode “Beat the Heat” security flaw heat map, State of Software Security Report v12 (Graphic: Business Wire)
Brian Roche, Chief Product Officer at Veracode, said, “Modern applications are mostly assembled, not written from scratch. Open-source code makes up a significant proportion of audited code bases—for example, 97 percent of the typical Java application is made up of open-source libraries*—increasing security risk and the need to identify supply chain risk. Our SBOM API, is designed to make it easier for developers to inventory their code base, including third-party components, allowing them to act quickly if new vulnerabilities emerge. Since the launch of our Continuous Software Security Platform in May, we have introduced additional capabilities that meet developers right where they work: in the integrated developer environment (IDE), code repository, and command line interface. These innovations are designed to drive adoption by making the platform even more developer friendly.”
Facilitating DevSecOps
Veracode’s platform supports 100+ languages and frameworks, including those for cloud-native application development and older languages used with legacy assets, like COBOL. Large enterprises have applications across myriad languages and being able to deploy a continuous security testing solution across them simplifies the process, while providing consistent results. The company’s latest State of Software Security (SoSS) 12 research analyzed the most common flaws by language and revealed that a prevalent flaw for one language may not be of any concern for another. For example, cross-site scripting (XSS) is the most common flaw for PHP, at 77 percent, but doesn’t even make the top 10 for C++*. Moreover, flaws change constantly, meaning that even if a flaw isn’t prevalent in a programming language, practitioners should still take active steps to prevent it from impacting their code. Since remediation tactics vary by flaw and programming language, having a broad array of language support in one place makes developers’ jobs easier by freeing up their time to focus on meeting tight deployment deadlines.
Frequent scanning of first- and third-party code mitigates the risk from both proprietary and open-source vulnerabilities, such as Log4j. Veracode’s new developer-centric tools and services are designed to make this a quicker and easier process, particularly with the additional capability of third-party proprietary library scanning.
Peter Evans, Engineering Director at QAD Precision GTTE, said, “Veracode brought a complete platform for us to build security tools into our development pipelines, as well as helped us grow our knowledge to keep getting better at security. Veracode was also a good fit because the platform can scan Java code in the Spring framework where we develop our software. We’ve gone from reviewing code to integrating continuous scans into our daily pipelines. Security threats don’t stand still and Veracode provides us the tools to keep up with the latest vulnerabilities and rules.”
Notable updates to the Veracode Continuous Software Security platform include:
SBOM for SCA
- With government regulations driving standards for securing software supply chains, having an SBOM is increasingly important for organizations. Veracode’s SBOM API in SCA enables developers to easily generate an SBOM in CycloneDX JSON format—one of the approved formats for compliance with the U.S. Executive Order. This helps confirm the code they’re using, or building, is free from vulnerabilities.
IDE and Integrations for SCA
To make software security a seamless experience, Veracode continues to introduce integrations that meet developers where they work.
- The Veracode Azure DevOps Extension has a new “SCA Flaw Importer” to automatically import SCA flaws into Azure DevOps Boards and Work Items
- The soon-to-be-released Veracode for Visual Studio Code extension provides detailed information on vulnerabilities, licence risks, and recommended versions of open-source libraries and transitive dependencies so developers can rapidly respond to any risks
Expanded Frameworks and Languages Support for Static Analysis
- The company is committed to keeping up with the latest language and frameworks with which developers work, adding support for Rails 7.0, Ruby 3.x, and PHP Symfony
Roche concluded, “As a pioneer of application security, we are uniquely positioned to combine unrivalled experience with the latest innovations in cloud development. Unlike on-premise vendors, our SaaS solution is both scalable and elastic, meaning customers are always prepared to meet unexpected demand. Powered by nearly two decades of cumulative data, our platform provides detailed comparative historical reviews against industry benchmarks and peers—a level of insight highly relevant for leadership teams and the board. Our platform also saves developers time by delivering highly accurate results and enabling them to find and fix vulnerabilities in minutes, meaning they can ship code quickly with the confidence that it is secure.”
Developers can learn more about Veracode’s platform, the frictionless developer experience, and how to simply and maturely secure their SDLC by visiting Veracode’s booth #2428 at Black Hat USA.
*Veracode State of Software Security Report v12, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities.
Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220809005141/en/
Contact information
Press and Media
Katy Gwilliam
Head of Global PR, Veracode
kgwilliam@veracode.com
+44.7584.341.110
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom